189 related articles for article (PubMed ID: 18253818)
21. Silibinin prevents prostate cancer cell-mediated differentiation of naïve fibroblasts into cancer-associated fibroblast phenotype by targeting TGF β2.
Ting HJ; Deep G; Jain AK; Cimic A; Sirintrapun J; Romero LM; Cramer SD; Agarwal C; Agarwal R
Mol Carcinog; 2015 Sep; 54(9):730-41. PubMed ID: 24615813
[TBL] [Abstract][Full Text] [Related]
22. The cancer preventive flavonoid silibinin causes hypophosphorylation of Rb/p107 and Rb2/p130 via modulation of cell cycle regulators in human prostate carcinoma DU145 cells.
Tyagi A; Agarwal C; Agarwal R
Cell Cycle; 2002; 1(2):137-42. PubMed ID: 12429923
[TBL] [Abstract][Full Text] [Related]
23. Prostate cancer chemoprevention by silibinin: bench to bedside.
Singh RP; Agarwal R
Mol Carcinog; 2006 Jun; 45(6):436-42. PubMed ID: 16637061
[TBL] [Abstract][Full Text] [Related]
24. Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels.
Singh RP; Dhanalakshmi S; Tyagi AK; Chan DC; Agarwal C; Agarwal R
Cancer Res; 2002 Jun; 62(11):3063-9. PubMed ID: 12036915
[TBL] [Abstract][Full Text] [Related]
25. Protein kinase C-{alpha} mediates epidermal growth factor receptor transactivation in human prostate cancer cells.
Stewart JR; O'Brian CA
Mol Cancer Ther; 2005 May; 4(5):726-32. PubMed ID: 15897236
[TBL] [Abstract][Full Text] [Related]
26. Ionizing radiation causes a dose-dependent release of transforming growth factor alpha in vitro from irradiated xenografts and during palliative treatment of hormone-refractory prostate carcinoma.
Hagan M; Yacoub A; Dent P
Clin Cancer Res; 2004 Sep; 10(17):5724-31. PubMed ID: 15355899
[TBL] [Abstract][Full Text] [Related]
27. A flavonoid antioxidant, silymarin, inhibits activation of erbB1 signaling and induces cyclin-dependent kinase inhibitors, G1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145 cells.
Zi X; Grasso AW; Kung HJ; Agarwal R
Cancer Res; 1998 May; 58(9):1920-9. PubMed ID: 9581834
[TBL] [Abstract][Full Text] [Related]
28. Leuprorelin acetate affects ERK1/2 activity in prostate cancer cells.
Iacopino F; Lama G; Angelucci C; Sica G
Int J Oncol; 2006 Jul; 29(1):237-47. PubMed ID: 16773205
[TBL] [Abstract][Full Text] [Related]
29. Silibinin suppresses EGFR ligand-induced CD44 expression through inhibition of EGFR activity in breast cancer cells.
Kim S; Han J; Kim JS; Kim JH; Choe JH; Yang JH; Nam SJ; Lee JE
Anticancer Res; 2011 Nov; 31(11):3767-73. PubMed ID: 22110198
[TBL] [Abstract][Full Text] [Related]
30. [Regulation of EGF-receptor expression by TGFalpha in human prostate androgen-unresponsive cancer cells].
Chen W; Yan C; Pu J; Hou J; Wen D; Guo Z
Zhonghua Nan Ke Xue; 2004 Aug; 10(8):595-7. PubMed ID: 15362522
[TBL] [Abstract][Full Text] [Related]
31. Silibinin inhibits UVB- and epidermal growth factor-induced mitogenic and cell survival signaling involving activator protein-1 and nuclear factor-kappaB in mouse epidermal JB6 cells.
Singh RP; Dhanalakshmi S; Mohan S; Agarwal C; Agarwal R
Mol Cancer Ther; 2006 May; 5(5):1145-53. PubMed ID: 16731746
[TBL] [Abstract][Full Text] [Related]
32. Increased expression of heparin binding EGF (HB-EGF), amphiregulin, TGF alpha and epiregulin in androgen-independent prostate cancer cell lines.
Tørring N; Jørgensen PE; Sørensen BS; Nexø E
Anticancer Res; 2000; 20(1A):91-5. PubMed ID: 10769639
[TBL] [Abstract][Full Text] [Related]
33. Involvement of transforming growth factor alpha (TGFalpha) and epidermal growth factor receptor (EGFR) in sex hormone-induced prostatic dysplasia and the growth of an androgen-independent transplantable carcinoma of the prostate.
Kaplan PJ; Leav I; Greenwood J; Kwan PW; Ho SM
Carcinogenesis; 1996 Dec; 17(12):2571-9. PubMed ID: 9006091
[TBL] [Abstract][Full Text] [Related]
34. Transforming growth factor alpha (TGFα) regulates granulosa cell tumor (GCT) cell proliferation and migration through activation of multiple pathways.
Wang C; Lv X; Jiang C; Cordes CM; Fu L; Lele SM; Davis JS
PLoS One; 2012; 7(11):e48299. PubMed ID: 23155381
[TBL] [Abstract][Full Text] [Related]
35. Prostate cancer prevention by silibinin.
Singh RP; Agarwal R
Curr Cancer Drug Targets; 2004 Feb; 4(1):1-11. PubMed ID: 14965263
[TBL] [Abstract][Full Text] [Related]
36. Silibinin suppresses in vivo growth of human prostate carcinoma PC-3 tumor xenograft.
Singh RP; Deep G; Blouin MJ; Pollak MN; Agarwal R
Carcinogenesis; 2007 Dec; 28(12):2567-74. PubMed ID: 17916909
[TBL] [Abstract][Full Text] [Related]
37. Epigallocatechin-3-gallate inhibits epidermal growth factor receptor signaling pathway. Evidence for direct inhibition of ERK1/2 and AKT kinases.
Sah JF; Balasubramanian S; Eckert RL; Rorke EA
J Biol Chem; 2004 Mar; 279(13):12755-62. PubMed ID: 14701854
[TBL] [Abstract][Full Text] [Related]
38. p21 and p27 induction by silibinin is essential for its cell cycle arrest effect in prostate carcinoma cells.
Roy S; Kaur M; Agarwal C; Tecklenburg M; Sclafani RA; Agarwal R
Mol Cancer Ther; 2007 Oct; 6(10):2696-707. PubMed ID: 17938263
[TBL] [Abstract][Full Text] [Related]
39. Silibinin inhibits aberrant lipid metabolism, proliferation and emergence of androgen-independence in prostate cancer cells via primarily targeting the sterol response element binding protein 1.
Nambiar DK; Deep G; Singh RP; Agarwal C; Agarwal R
Oncotarget; 2014 Oct; 5(20):10017-33. PubMed ID: 25294820
[TBL] [Abstract][Full Text] [Related]
40. Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines.
Putz T; Culig Z; Eder IE; Nessler-Menardi C; Bartsch G; Grunicke H; Uberall F; Klocker H
Cancer Res; 1999 Jan; 59(1):227-33. PubMed ID: 9892211
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
